Corcept Therapeutics Incorporated $CORT Stock: Intech Investment Management LLC Reduces Stake

Intech Investment Management LLC lowered its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) by 23.2% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 29,191 shares of the biotechnology company’s stock after selling 8,801 shares during the quarter. Intech Investment Management LLC’s holdings in Corcept Therapeutics were worth $3,364,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. Allworth Financial LP increased its position in Corcept Therapeutics by 3.8% in the third quarter. Allworth Financial LP now owns 4,039 shares of the biotechnology company’s stock worth $465,000 after purchasing an additional 147 shares during the period. Quadrant Capital Group LLC lifted its position in Corcept Therapeutics by 1.3% during the 3rd quarter. Quadrant Capital Group LLC now owns 14,007 shares of the biotechnology company’s stock valued at $1,650,000 after purchasing an additional 178 shares during the period. Envestnet Portfolio Solutions Inc. lifted its position in Corcept Therapeutics by 1.8% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 10,617 shares of the biotechnology company’s stock valued at $923,000 after purchasing an additional 184 shares during the period. State of Wyoming boosted its stake in shares of Corcept Therapeutics by 29.5% in the 1st quarter. State of Wyoming now owns 816 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 186 shares during the last quarter. Finally, Wedmont Private Capital boosted its stake in shares of Corcept Therapeutics by 6.1% in the 3rd quarter. Wedmont Private Capital now owns 3,329 shares of the biotechnology company’s stock valued at $395,000 after purchasing an additional 190 shares during the last quarter. Institutional investors and hedge funds own 93.61% of the company’s stock.

Corcept Therapeutics Stock Down 4.1%

CORT opened at $64.98 on Friday. Corcept Therapeutics Incorporated has a 12 month low of $28.66 and a 12 month high of $126.38. The company has a fifty day simple moving average of $100.01 and a 200 day simple moving average of $76.94. The stock has a market cap of $7.11 billion, a P/E ratio of 51.17 and a beta of 0.54.

Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last issued its quarterly earnings data on Tuesday, November 3rd. The biotechnology company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.84 by $0.17. The business had revenue of $340.47 million for the quarter, compared to the consensus estimate of $339.12 million. Corcept Therapeutics had a return on equity of 22.56% and a net margin of 16.53%. The firm’s revenue was up 64.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.16 EPS. On average, equities research analysts expect that Corcept Therapeutics Incorporated will post 1.97 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director James Wilson sold 10,000 shares of the firm’s stock in a transaction dated Friday, November 13th. The stock was sold at an average price of $72.67, for a total transaction of $726,700.00. Following the sale, the director owned 1,044,543 shares of the company’s stock, valued at $75,906,939.81. This trade represents a 0.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Sean Maduck sold 13,159 shares of the firm’s stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $82.25, for a total value of $1,082,327.75. Following the sale, the insider directly owned 9,938 shares in the company, valued at approximately $817,400.50. This represents a 56.97% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 259,435 shares of company stock valued at $28,492,179. 20.70% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Canaccord Genuity Group boosted their price target on shares of Corcept Therapeutics from $135.00 to $150.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. HC Wainwright restated a “buy” rating and issued a $165.00 price objective on shares of Corcept Therapeutics in a report on Friday, September 18th. Wolfe Research cut shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 price objective on the stock. in a research note on Monday, July 27th. Zacks Research lowered shares of Corcept Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 27th. Finally, Wall Street Zen raised shares of Corcept Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 1st. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $139.50.

Read Our Latest Analysis on CORT

Corcept Therapeutics Company Profile

(Free Report)

Corcept Therapeutics is a biopharmaceutical company focused on developing medicines that modulate the effects of cortisol, a hormone involved in the body’s response to stress and in several disease processes. Founded in 1998, the company conducts research and develops treatments for conditions in which cortisol may play a role. Its marketed product, Korlym (mifepristone), is approved in the United States to control high blood sugar in adults with endogenous Cushing’s syndrome who have type 2 diabetes or glucose intolerance and are not candidates for surgery or have not benefited from it.

Further Reading

Want to see what other hedge funds are holding CORT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report).

Institutional Ownership by Quarter for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.